Cagrilintide
Also known as: Cagri, AM833, Cagrilintide acetate
Classification
Peptide
Regulatory Status
n/a
Sources
2
Review
n/a
Overview
Cagrilintide is a long-acting amylin analogue that engages amylin and calcitonin receptors to reduce energy intake. It has been studied alone and with GLP-1 agonists for weight management but is not an approved drug in this record.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Interactions & cautions
Drug interactions
GLP-1 receptor agonists and other incretin/amylin agents — Additive GI adverse effects expected; combination regimens belong in controlled clinical contexts. (high)
These are observational flags for review, not individualized instructions.
Sources
- https://www.acc.org/latest-in-cardiology/journal-scans/2025/07/02/14/43/redefine-1-and-redefine-2
- PubMed search: cagrilintide obesity (opens in a new tab)
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw